Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors
Summary: JAK inhibitors impact multiple cytokine pathways simultaneously, enabling high efficacy in treating complex diseases such as cancers and immune-mediated disorders. However, their broad reach also poses safety concerns, which have fuelled a demand for increasingly selective JAK inhibitors.De...
Main Authors: | Lise Torp Jensen, Kathrine E. Attfield, Marc Feldmann, Lars Fugger |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-11-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396423004061 |
Similar Items
-
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
by: Potestio L, et al.
Published: (2023-05-01) -
Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases
by: Zhiqin Fang, et al.
Published: (2023-11-01) -
Deucravacitinib in the treatment of psoriasis
by: Tomás Estevinho, et al.
Published: (2023-12-01) -
The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
by: Jingyue Qiu, et al.
Published: (2023-09-01) -
A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis
by: Francisco Gómez-García, et al.
Published: (2022-02-01)